BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease
Links shared publicly online about this topic.
- 792total visits
BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease
Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of BARACLUDE for the treatment of chronic hepatitis B (CHB) in adult patients with decompensated liver disease.
View full resource at news-medical.net
Tags: Liver, Liver Condition, Hepatitis B Medication, Pregnancy, FDA, Baraclude, News
Most Recently Shared on October 18, 2010 at 9:19 pm By:
Pregnancy News: BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver diseas... http://bit.ly/c7NTU3
Advertisement
